Literature DB >> 24680405

[Relationship between expression of microRNA and inflammatory cytokines plasma level in pediatric patients with sepsis].

Yuhui Wu1, Chengrong Li2, Yanxia He, Qiu Li, Guobing Wang, Pengqiang Wen, Weiguo Yang, Yanlan Yang.   

Abstract

OBJECTIVE: Sepsis is the major cause of death in pediatric intensive care unit (PICU). The clinical manifestations of early sepsis is very similar to systemic inflammatory response syndrome (SIRS) caused by non-infectious reason. This study aimed to investigate the expression of miRNA and inflammatory cytokines in plasma in pediatric sepsis patients and its clinical significance.
METHOD: Forty children with sepsis seen in Shenzhen children's hospital PICU from April 2012 to March 2013 were enrolled in this study, the median age was 0.75 (0.52, 1.90) years; 27 were males and 13 females, of whom 16 had severe sepsis. We selected 20 postsurgical patients with SIRS and 15 healthy children as a control group. The expression levels of plasma miR-21, miR-125b, miR-132, miR-146a, miR-155 and miR-223 were detected by real-time quantitative PCR (qRT-PCR). The predictive value of miRNA, PCT and CRP for sepsis were evaluated by Receiver operating characteristic curve (ROC). TNF-α and IL-10 levels in plasma detected by Cytometric Beads Array (CBA). Quantitative data of normal distribution was compared with ANOVA among the three groups and LSD-t test between two groups. To non-normal distribution of data, multiple comparisons among three groups were conducted by Kruskal-Wallis H test and differences between two groups were assessed by Mann-Whitney U test for post hoc analysis. RESULT: There were no significant differences between the age and gender of each group. Expression of miR-21, miR-125b, miR-132 and miR-155 in plasma had no significant difference in each group (all P > 0.05). MiR-146a and miR-223 levels in sepsis were upregulated compared with SIRS group and control group [(5.7 ± 3.5)×10(-5) vs. (2.4 ± 1.6)×10(-5) and (2.6 ± 1.2)×10(-5), (12.5 ± 7.7)×10(-4) vs. (8.3 ± 3.4)×10(-4) and (5.3 ± 2.2)×10(-4), all P < 0.01], expression levels of miR-223 in SIRS increased as compared to control group (P < 0.01). MiR-146a levels in severe sepsis were higher than those of the general sepsis [ (7.1 ± 3.3)×10(-5) vs. (4.6 ± 2.6)×10(-5), P < 0.01]. CRP and PCT levels are all higher in sepsis and SIRS groups than control group (all P < 0.01). The area under ROC curve (AUC) of miR-146a, miR-223, PCT and CRP to predict sepsis were 0.815 (95%CI: 0.708-0.922), 0.678(95%CI: 0.537-0.818), 0.706 (95%CI: 0.571-0.842) and 0.588 (95%CI: 0.427-0.748). Expression levels of IL-10 and IL-10/TNF-α in sepsis were upregulated compared with and SIRS group and the control group (all P < 0.01). There was a positive correlation between miR-146a, miR-223 and IL-10 and IL-10/TNF-α (r = 0.545, 0.305, 0.562, 0.373, all P < 0.01).
CONCLUSION: The expression levels of miR-146a and miR-223 in plasma in pediatric patients with sepsis was significantly upregulated, and had a positive correlation with IL-10 and IL-10/TNF-α, which may be used as early diagnostic markers and can reflect the severity of condition to a certain degree.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24680405

Source DB:  PubMed          Journal:  Zhonghua Er Ke Za Zhi        ISSN: 0578-1310


  13 in total

Review 1.  Non-Coding RNA Networks as Potential Novel Biomarker and Therapeutic Target for Sepsis and Sepsis-Related Multi-Organ Failure.

Authors:  Domenico Di Raimondo; Edoardo Pirera; Giuliana Rizzo; Irene Simonetta; Gaia Musiari; Antonino Tuttolomondo
Journal:  Diagnostics (Basel)       Date:  2022-05-31

Review 2.  Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers.

Authors:  Perry V Halushka; Andrew J Goodwin; Marc K Halushka
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

3.  Values of circulating molecular biomarkers (microRNAs) for the evaluation of renal failure during urgent abdominal sepsis anaesthesia.

Authors:  Tomas Bukauskas; Monika Kairytė; Rytis Mickus; Loreta Puleikytė; Andrius Macas
Journal:  Acta Med Litu       Date:  2019

4.  microRNA-23b regulates the expression of inflammatory factors in vascular endothelial cells during sepsis.

Authors:  Ming Wu; Jian-Teng Gu; Bin Yi; Zhong-Zhi Tang; Guo-Cai Tao
Journal:  Exp Ther Med       Date:  2015-01-28       Impact factor: 2.447

Review 5.  The involvement of regulatory non-coding RNAs in sepsis: a systematic review.

Authors:  Jeffery Ho; Hung Chan; Sunny H Wong; Maggie H T Wang; Jun Yu; Zhangang Xiao; Xiaodong Liu; Gordon Choi; Czarina C H Leung; Wai T Wong; Zheng Li; Tony Gin; Matthew T V Chan; William K K Wu
Journal:  Crit Care       Date:  2016-11-28       Impact factor: 9.097

6.  Research on the effect of cytokine concentration on the immune level and survival conditions of elderly patients with sepsis.

Authors:  Xuguang Li; Biqing Yan
Journal:  Exp Ther Med       Date:  2018-05-24       Impact factor: 2.447

Review 7.  Cellular and viral microRNAs in sepsis: mechanisms of action and clinical applications.

Authors:  Dana Elena Giza; Enrique Fuentes-Mattei; Marc David Bullock; Stefan Tudor; Matthew Joseph Goblirsch; Muller Fabbri; Florea Lupu; Sai-Ching Jim Yeung; Catalin Vasilescu; George Adrian Calin
Journal:  Cell Death Differ       Date:  2016-10-14       Impact factor: 15.828

Review 8.  Circulating MicroRNAs as Biomarkers for Sepsis.

Authors:  Fabian Benz; Sanchari Roy; Christian Trautwein; Christoph Roderburg; Tom Luedde
Journal:  Int J Mol Sci       Date:  2016-01-09       Impact factor: 5.923

Review 9.  Expression Levels of Candidate Circulating microRNAs in Early-Onset Neonatal Sepsis Compared With Healthy Newborns.

Authors:  Benet B Dhas; Vijaya R Dirisala; B Vishnu Bhat
Journal:  Genomics Insights       Date:  2018-09-02

10.  MicroRNAs 143 and 150 in whole blood enable detection of T-cell immunoparalysis in sepsis.

Authors:  P Möhnle; S Hirschberger; L C Hinske; J Briegel; M Hübner; S Weis; G Dimopoulos; M Bauer; E J Giamarellos-Bourboulis; S Kreth
Journal:  Mol Med       Date:  2018-10-17       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.